Browse EPN3

Summary
SymbolEPN3
Nameepsin 3
Aliases FLJ20778; MGC129899; EPS-15-interacting protein 3; Epsin-3
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Cytoplasm, perinuclear region Cytoplasmic vesicle, clathrin-coated vesicle Nucleus Note=Concentrated in the perinuclear region and associated with clathrin-coated vesicles close to the cell periphery. May shuttle to the nucleus.
Domain PF01417 ENTH domain
PF02809 Ubiquitin interaction motif
Function

-

> Gene Ontology
 
Biological Process -
Molecular Function GO:1990175 EH domain binding
Cellular Component GO:0005905 clathrin-coated pit
GO:0019897 extrinsic component of plasma membrane
GO:0019898 extrinsic component of membrane
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0098589 membrane region
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
Reactome -
Summary
SymbolEPN3
Nameepsin 3
Aliases FLJ20778; MGC129899; EPS-15-interacting protein 3; Epsin-3
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between EPN3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolEPN3
Nameepsin 3
Aliases FLJ20778; MGC129899; EPS-15-interacting protein 3; Epsin-3
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of EPN3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolEPN3
Nameepsin 3
Aliases FLJ20778; MGC129899; EPS-15-interacting protein 3; Epsin-3
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of EPN3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.4410.312
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1050.889
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.8480.206
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2550.654
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6050.804
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2010.941
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1260.883
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7130.631
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.0770.494
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1420.0471
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.2120.105
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.2670.215
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of EPN3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolEPN3
Nameepsin 3
Aliases FLJ20778; MGC129899; EPS-15-interacting protein 3; Epsin-3
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of EPN3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolEPN3
Nameepsin 3
Aliases FLJ20778; MGC129899; EPS-15-interacting protein 3; Epsin-3
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of EPN3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by EPN3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolEPN3
Nameepsin 3
Aliases FLJ20778; MGC129899; EPS-15-interacting protein 3; Epsin-3
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of EPN3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolEPN3
Nameepsin 3
Aliases FLJ20778; MGC129899; EPS-15-interacting protein 3; Epsin-3
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of EPN3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolEPN3
Nameepsin 3
Aliases FLJ20778; MGC129899; EPS-15-interacting protein 3; Epsin-3
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between EPN3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolEPN3
Nameepsin 3
Aliases FLJ20778; MGC129899; EPS-15-interacting protein 3; Epsin-3
Chromosomal Location17q21.33
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting EPN3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.